Breaking News
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Better Pharma Stock: Eli Lilly or Sanofi?

Stock MarketsJun 04, 2021 11:30AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. Better Pharma Stock: Eli Lilly or Sanofi?

The COVID-19 pandemic has reshaped the pharmaceutical industry in a big way because it highlighted its role in fighting the virus by developing effective medications and vaccines quickly. In fact, as the accelerated pace of digitization continues to broaden the industry’s horizon of possibilities, we think pharmaceutical giants Eli Lilly (LLY) and Sanofi (NASDAQ:SNY) should witness further growth. But let’s find out which of these stocks is a better buy now.Eli Lilly and Company (NYSE:LLY) and Sanofi (SNY) develop, manufacture, and market pharmaceuticals and therapeutic solutions worldwide. LLY offers Cyramza for metastatic gastric cancer, Baqsimi for severe hypoglycemia, Bamlanivimab and etesevimab for COVID-19, among other drugs. Based in Paris, SNY provides products for multiple sclerosis, neurology, and other inflammatory diseases. Also, it has a collaboration with GlaxoSmithKline (NYSE:GSK) to develop a recombinant COVID-19 vaccine.

The global pharmaceuticals market is expected to grow at a 1.8% CAGR--from $1228.45 billion in 2020 to $1250.24 billion in 2021. Rapid investment in drugs for customized treatment and therapies and personalized medicine have been driving the industry’s growth in recent years. But the COVID-19 pandemic has been a transformational moment for the industry, highlighting its ability to rapidly deliver solutions to fight the virus. And now that pharmaceutical companies are capitalizing on technologies to provide more holistic and patient-oriented products and services, it is poised to grow at an unprecedented pace. As such, we think SNY’s and LLY’s product portfolios should continue to improve with technological innovation, which should continue driving their growth.

LLY has gained 29.4% over the past year, while SNY has returned 3.9% over the same period. Also, in terms of year-to-date performance, LLY has surpassed SNY’s 6.7% gains with 17.9% gains. But which of these stocks is a better pick now? Let’s find out.

Continue reading on StockNews

Better Pharma Stock: Eli Lilly or Sanofi?

Related Articles

Wall Street pivots to value as Treasury yields rise
Wall Street pivots to value as Treasury yields rise By Reuters - Sep 27, 2021 7

By Stephen Culp NEW YORK (Reuters) - Wall Street began the last week of September and the quarter with investors backing value over growth on Monday as tech shares, hurt by rising...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email